• Overall Procedure Time [ Time Frame: During Procedure ]
  Defined as time from initial catheter insertion to final catheter removal.
• Radiofrequency (RF) Time [ Time Frame: During Procedure ]
  Defined as duration of time RF energy is delivered
• Fluoroscopy time [ Time Frame: During Procedure ]
  Defined as total time subject is exposed to fluoroscopy
• Mapping time associated with mapping arrhythmia [ Time Frame: During Procedure ]
  Defined as the total cumulative mapping time and mapping time for the creation of each map (including any new or retrospective map created with Manual, AutoMap, and TurboMap mapping)
• Number of mapping points collected [ Time Frame: During Procedure ]
  Defined as total number of mapping points collected for the creation of each map
• Number of mapping points used [ Time Frame: During Procedure ]
  Defined as the total number of mapping points used in each map
• Number of used mapping points per minute [ Time Frame: During Procedure ]
  Defined as the total number of mapping points used divided by the relative mapping time
• Substrate characteristics identified [ Time Frame: During Procedure ]
  For each type of arrhythmogenic substrate this will be defined as the frequency of substrate type identified in cases that attempted to identify the specific substrate
• Ablation strategy(s) used [ Time Frame: During Procedure ]
  Defined by both the type of map used to define ablation strategy and the frequency each ablation strategy/target was used by physicians

• Number of participants with adverse events [ Time Frame: through study completion, an average of 1 year ]
  Adverse events include any device-, procedure-, or death-related events
• Rate of repeat ablations [ Time Frame: through study completion, an average of 1 year ]
  Defined as proportion of subjects with an additional ablation procedure to treat indicated cardiac arrhythmia (outside blanking period, if applicable).
• Change in Quality of Life (QoL): EQ-5D-5L [ Time Frame: through study completion, an average of 1 year ]
  Defined as change in quality of life score assessed by the validated QoL survey, EQ-5D-5L. The EQ-5D-5L is a descriptive system comprised of five questions related to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each question has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

• Adverse events [ Time Frame: through study completion, an average of 1 year ]
  Adverse events including any device-, procedure-, or death-related events
• Rate of repeat ablations [ Time Frame: through study completion, an average of 1 year ]
  Defined as proportion of subjects with an additional ablation procedure to treat indicated cardiac arrhythmia (outside blanking period, if applicable).
• Change in Quality of Life (QoL): EQ-5D-5L [ Time Frame: through study completion, an average of 1 year ]
  Defined as change in quality of life assessed in validated QoL surveys (EQ-5D-5L)

• Paroxysmal Atrial Fibrillation
• Persistent Atrial Fibrillation

• Inquiry™ AFocusII™ Double Loop
  The Inquiry™ AFocus™ catheters are for recording intracardiac signals and cardiac stimulation during diagnostic electrophysiological studies. The Inquiry™ AFocus™ catheters are for use in mapping atrial regions of the heart.
  Intervention: Device: Catheter ablation
• Advisor™ HD Grid, Sensor Enabled™
  The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart with recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
  Intervention: Device: Catheter ablation

Inclusion Criteria:

1. Subject must provide written informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule
2. Subject must be over 18 years of age. (In Japan, the subject must be of 20 years of age or older)

3. Subject is diagnosed with AF as defined by:

   • Documented symptomatic paroxysmal AF defined as AF that terminates spontaneously or with intervention within 7 days of onset
   • Documented symptomatic persistent AF defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 12 months
4. Subject is indicated for cardiac electroanatomical mapping and RF ablation procedure to treat AF
5. Subject is planned to have electroanatomical mapping performed with the HD mapping catheters under investigation

Exclusion Criteria:

1. Previous ablation or surgery in the left atria
2. Implanted left atrial appendage occluder
3. Implanted mitral or tricuspid valve replacement
4. Implanted cardiac defibrillator (ICD)
5. Participation in another clinical investigation that may confound the results of this study
6. Pregnant or nursing
7. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
8. Life expectancy less than 12 months